Soligenix

Soligenix Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases and other conditions with unmet medical needs. Its core business is organized into two segments: Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops treatments for orphan and inflammatory diseases, including cutaneous T-cell lymphoma, psoriasis, oral mucositis, and Behçet’s disease. The Public Health Solutions segment works on vaccines and therapeutics for biodefense and infectious disease threats, including ricin exposure, Ebola, Marburg, and other emerging viral infections. Soligenix Inc. plays a niche role in the healthcare market by targeting areas where treatment options remain limited, combining rare disease development with medical countermeasure research.